Rigel Pharmaceuticals (RIGL) Research & Development (2010 - 2026)

Rigel Pharmaceuticals has reported Research & Development for 17 years, with the latest figure at $11.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 38.41% year-over-year to $11.7 million; the trailing twelve-month figure through Mar 2026 stood at $36.5 million (up 41.66% YoY), and the FY2025 full-year result was $33.3 million, up 42.41% from the prior year.
• Research & Development for Q1 2026 stood at $11.7 million, up from $10.7 million in the prior quarter.
• The five-year high for Research & Development was $15.5 million in Q1 2022, with the low at $2.5 million in Q4 2022.
• Average Research & Development over 5 years is $8.3 million, with a median of $6.8 million recorded in 2025.
• Year-over-year, Research & Development slumped 81.21% in 2022 and surged 89.72% in 2025.
• Tracing RIGL's Research & Development over 5 years: stood at $2.5 million in 2022, then increased by 27.44% to $3.2 million in 2023, then surged by 76.77% to $5.6 million in 2024, then surged by 89.72% to $10.7 million in 2025, then climbed by 9.27% to $11.7 million in 2026.
• The last three Research & Development figures came in at $11.7 million (Q1 2026), $10.7 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.

Peer Comparison